Skeletal disorders

Arthritis National Research Foundation Awards 18 New Research Grants

Thursday, May 6, 2021 - 2:00pm

b'The Arthritis National Research Foundation (ANRF) is proud to announce the awarding of 18 new research grants to scientists across the U.S. with bold new ideas for the treatment of arthritis and related autoimmune conditions.

Key Points: 
  • b'The Arthritis National Research Foundation (ANRF) is proud to announce the awarding of 18 new research grants to scientists across the U.S. with bold new ideas for the treatment of arthritis and related autoimmune conditions.
  • Ultimately, they selected 18 projects that could represent the future of diagnostics and treatments across the spectrum of autoimmune diseases.
  • These include Rheumatoid Arthritis, Juvenile Arthritis, Spondylarthritis, Osteoarthritis, Lupus, Scleroderma, and infection-induced autoimmunity in COVID-19 patients.
  • This commitment is shared by our community of individual supporters and bolstered by new industry partnerships.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210506005200/en/\n'

CBDMEDIC™ Announces Partnership With U.S. Women's and Olympic Soccer Star, Carli Lloyd

Wednesday, May 5, 2021 - 1:33pm

Lloyd partnered with CBDMEDIC after beginning to use its safe and effective topical CBD products following a knee injury and surgery last year.

Key Points: 
  • Lloyd partnered with CBDMEDIC after beginning to use its safe and effective topical CBD products following a knee injury and surgery last year.
  • Lloyd attributes her use of CBDMEDIC as a key factor in her recovery.\n"Taking care of and listening to our bodies is extremely important, especially when it comes to pain relief," said Lloyd.
  • "\nDuring her recovery, Lloyd began using CBDMEDIC topical products, including Active Sport Pain Relief Ointment and Active Sport Pain Relief Stick, which offer temporary relief of sore muscles.
  • She also applies CBDMEDIC Arthritis Aches and Pain Relief Cream, which is effective in relieving joint pain and stiffness.

Paragon 28, Inc. Receives FDA Clearance and Successfully Completes First MAVEN™ Patient-Specific Instrumentation Surgery

Tuesday, May 4, 2021 - 9:55pm

MAVEN PSI is compatible with both weight-bearing CT and traditional CT scanning technologies and features one continuous scan from the knee through the base of the foot to capture biomechanically accurate data.

Key Points: 
  • MAVEN PSI is compatible with both weight-bearing CT and traditional CT scanning technologies and features one continuous scan from the knee through the base of the foot to capture biomechanically accurate data.
  • The System introduces a perfect blend of performance and reliability.
  • MAVEN PSI also allows for refined intra-operative positioning and micro adjustments if necessary.
  • With this comprehensive portfolio, Paragon 28 provides its customers innovative ankle solutions for trauma, arthritis, and limbsalvage.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/paragon-28-inc-receives-fda-clea...\n'

Anika to Participate in Upcoming Virtual Investor Conferences

Tuesday, May 4, 2021 - 3:30pm

We partner with clinicians to understand what they need most to treat their patients and we develop minimally invasive products that restore active living for people around the world.

Key Points: 
  • We partner with clinicians to understand what they need most to treat their patients and we develop minimally invasive products that restore active living for people around the world.
  • We are committed to leading in high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies.
  • Anika is headquartered in Massachusetts with operations in the United States and Europe.
  • For more information about Anika, please visit www.anika.com .\n'

Voltaren Arthritis Pain Gel Empowers Early Morning Risers Living with Osteoarthritis

Monday, May 3, 2021 - 2:37pm

While 35% described themselves as early birds prior to being diagnosed with OA, only one-quarter are still early risers since learning they have OA.\nJoint pain can also impact the livelihoods of people with OA.

Key Points: 
  • While 35% described themselves as early birds prior to being diagnosed with OA, only one-quarter are still early risers since learning they have OA.\nJoint pain can also impact the livelihoods of people with OA.
  • An alternative to pills, Voltaren is applied directly to the site of pain, delivering powerful arthritis pain relief.
  • It is indicated for the treatment of arthritis pain in the hand, wrist, elbow, foot, ankle or knee.
  • To learn more about Voltaren, visit www.voltarengel.com .\nAn alternative to pills, Voltaren Arthritis Pain Gel targets pain directly at the source to deliver clinically-proven nonsteroidal anti-inflammatory medicine for powerful arthritis pain relief with a proven safety profile.

Arthritis Foundation Kicks Off Arthritis Awareness Month with Release of Key Findings from Patient Study, Announces Launch of New App

Monday, May 3, 2021 - 2:00pm

The report also comes with the announcement of a new tool to help arthritis patients manage their chronic pain: Vim, the Arthritis Foundation\'s mobile app.\nThe second annual report showcases key findings from the Arthritis Foundation\'s ongoing Live Yes!

Key Points: 
  • The report also comes with the announcement of a new tool to help arthritis patients manage their chronic pain: Vim, the Arthritis Foundation\'s mobile app.\nThe second annual report showcases key findings from the Arthritis Foundation\'s ongoing Live Yes!
  • Notable statistics also show that arthritis patients experience higher levels of pain than the rest of the population who reports to be in pain.
  • Sign up at arthritis.org/Vim to be the first to know when it\'s released.\nThe Arthritis Foundation is fighting for all people who live with arthritis.
  • As a Champion of Yes, it\'s the Arthritis Foundation\'s mission to turn the obstacles arthritis causes into opportunities.

New data presented at OARSI 2021 Virtual World Congress by AKL Research and Development advances understanding of biological effects of its investigational osteoarthritis drug APPA to protect against joint damage

Thursday, April 29, 2021 - 8:00am

Despite advances in understanding the pathological processes that underlie this, our best treatments today remain embarrassingly crude cut out the sore joint or prescribe painkillers.

Key Points: 
  • Despite advances in understanding the pathological processes that underlie this, our best treatments today remain embarrassingly crude cut out the sore joint or prescribe painkillers.
  • This builds on earlier research looking at neutrophils which showed that APPA may have significant anti-inflammatory potential.
  • "\nRegulatory guidance from the FDA states that any new OA drug targeting disease modification must also demonstrate symptomatic pain relief.
  • For more information, visit: https://www.aklrd.com/\n[3]FOOD AND DRUG ADMINISTRATION: Osteoarthritis: Structural Endpoints for the Development of Drugs, Devices, and Biological Products for Treatment Guidance for Industry.

New data presented at OARSI 2021 Virtual World Congress by AKL Research and Development advances understanding of biological effects of its investigational osteoarthritis drug APPA to protect against joint damage

Thursday, April 29, 2021 - 8:00am

Despite advances in understanding the pathological processes that underlie this, our best treatments today remain embarrassingly crude cut out the sore joint or prescribe painkillers.

Key Points: 
  • Despite advances in understanding the pathological processes that underlie this, our best treatments today remain embarrassingly crude cut out the sore joint or prescribe painkillers.
  • This builds on earlier research looking at neutrophils which showed that APPA may have significant anti-inflammatory potential.
  • "\nRegulatory guidance from the FDA states that any new OA drug targeting disease modification must also demonstrate symptomatic pain relief.
  • For more information, visit: https://www.aklrd.com/\n[3]FOOD AND DRUG ADMINISTRATION: Osteoarthritis: Structural Endpoints for the Development of Drugs, Devices, and Biological Products for Treatment Guidance for Industry.

Flexion Therapeutics Announces Presentation of Preliminary FX201 Clinical Data at the Upcoming 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Wednesday, April 28, 2021 - 12:30pm

We look forward to providing updated data from this cohort at ASGCT on May\xc2\xa011.\xe2\x80\x9d\nThe clinical data will be presented in a digital presentation entitled, Interim Data from the First-in-Human Phase 1 Trial of FX201, An Intra-Articular, Helper-Dependent Adenoviral Gene Therapy for Osteoarthritis - Safety, Tolerability, Biodistribution, and Preliminary Evaluation of Clinical Activity in 5 Patients ( Abstract 594 ).

Key Points: 
  • We look forward to providing updated data from this cohort at ASGCT on May\xc2\xa011.\xe2\x80\x9d\nThe clinical data will be presented in a digital presentation entitled, Interim Data from the First-in-Human Phase 1 Trial of FX201, An Intra-Articular, Helper-Dependent Adenoviral Gene Therapy for Osteoarthritis - Safety, Tolerability, Biodistribution, and Preliminary Evaluation of Clinical Activity in 5 Patients ( Abstract 594 ).
  • The company's core values are focus, ingenuity, tenacity, transparency, and fun.
  • Please visit flexiontherapeutics.com .\nThis press release contains forward-looking statements that are based on the current expectations and beliefs of Flexion.
  • We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.\n"

Bioventus Announces First Commercial Shipment of the Bioness® Integrated Therapy System (BITS) Balance System

Tuesday, April 27, 2021 - 1:30pm

b"VALENCIA, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (\xe2\x80\x9cBioventus\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d), a global leader in innovations for active healing, announced the first commercial shipments of the Bioness Integrated Therapy System (BITS) for Balance.

Key Points: 
  • b"VALENCIA, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (\xe2\x80\x9cBioventus\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d), a global leader in innovations for active healing, announced the first commercial shipments of the Bioness Integrated Therapy System (BITS) for Balance.
  • The Innovations for Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing.
  • With the recent acquisition of Bioness, Inc., Bioventus expanded product offerings now include products for acute and chronic pain, central nervous system disorders including stroke and orthopedic injuries.
  • For more information, visit www.bioventus.com , www.bioness.com and follow the Company on LinkedIn and Twitter .\nBioventus and the Bioventus logo are registered trademarks of Bioventus LLC.